Charlene So

3.9k total citations
8 papers, 273 citations indexed

About

Charlene So is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Charlene So has authored 8 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Hematology and 2 papers in Rheumatology. Recurrent topics in Charlene So's work include Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (2 papers). Charlene So is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (2 papers). Charlene So collaborates with scholars based in United States, Switzerland and France. Charlene So's co-authors include François Guilhot, Brian Druker, Richard A. Larson, Joëlle Guilhot, Steve O’Brien, Giorgio Massimini, Lydia Roy, Tillmann Krahnke, Agnès Guerci‐Bresler and Insa Gathmann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Charlene So

8 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charlene So United States	5	257	224	158	26	22	8	273
G. J. Ossenkoppele Netherlands	10	263 1.0×	206 0.9×	134 0.8×	47 1.8×	27 1.2×	17	279
Franck E. Nicolini France	3	180 0.7×	160 0.7×	117 0.7×	13 0.5×	15 0.7×	6	190
Bronte A. Jamison Australia	5	307 1.2×	262 1.2×	148 0.9×	41 1.6×	41 1.9×	5	327
Alicia Enrico Argentina	5	198 0.8×	177 0.8×	117 0.7×	26 1.0×	33 1.5×	13	227
Alexandra L. Yeoman Australia	5	310 1.2×	263 1.2×	149 0.9×	42 1.6×	42 1.9×	6	330
G Marzocchi Italy	4	148 0.6×	112 0.5×	84 0.5×	22 0.8×	19 0.9×	6	167
Carla Boquimpani Brazil	9	231 0.9×	199 0.9×	108 0.7×	21 0.8×	60 2.7×	29	241
Susanne Jung-Munkwitz Germany	4	230 0.9×	207 0.9×	139 0.9×	22 0.8×	16 0.7×	5	235
Stuart Phillis Australia	5	258 1.0×	223 1.0×	126 0.8×	24 0.9×	52 2.4×	6	295
Jeffrey Skinner United States	6	188 0.7×	162 0.7×	94 0.6×	18 0.7×	40 1.8×	16	220

Countries citing papers authored by Charlene So

Since Specialization

Citations

This map shows the geographic impact of Charlene So's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene So with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene So more than expected).

Fields of papers citing papers by Charlene So

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene So. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene So. The network helps show where Charlene So may publish in the future.

Co-authorship network of co-authors of Charlene So

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene So. A scholar is included among the top collaborators of Charlene So based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene So. Charlene So is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Porter, David L., Norbert Frey, Alison W. Loren, et al.. (2013). A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). TPS7132–TPS7132. 2 indexed citations

Deininger, Michael W., Jörge E. Cortes, Ron Paquette, et al.. (2007). The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells. Cancer. 110(7). 1509–1519. 74 indexed citations

Roy, Lydia, Joëlle Guilhot, Tillmann Krahnke, et al.. (2006). Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 108(5). 1478–1484. 157 indexed citations

Larson, Richard A., Brian Druker, François Guilhot, et al.. (2006). Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.. Blood. 108(11). 429–429. 12 indexed citations

Kaeda, Jaspal, Andreas Hochhaus, Jerald P. Radich, et al.. (2006). Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1st Line IM Patients.. Blood. 108(11). 2139–2139. 1 indexed citations

Goldman, John M., Timothy P. Hughes, Jerry Radich, et al.. (2005). Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.. Blood. 106(11). 163–163. 20 indexed citations

Deininger, Michael W., Hagop M. Kantarjian, Andreas Hochhaus, et al.. (2005). Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.. Blood. 106(11). 1082–1082. 2 indexed citations

Guilhot, François, Lydia Roy, Joëlle Guilhot, et al.. (2005). Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).. Blood. 106(11). 165–165. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact